SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 3,252.44 |
Enterprise Value ($M) | 6,542.24 |
Book Value ($M) | 4,566.00 |
Book Value / Share | 33.47 |
Price / Book | 0.71 |
NCAV ($M) | -2,929.40 |
NCAV / Share | -21.47 |
Price / NCAV | -1.11 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.02 |
Return on Assets (ROA) | -0.01 |
Return on Equity (ROE) | -0.03 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.77 |
Current Ratio | 2.56 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 3,707.80 |
Assets | 11,203.20 |
Liabilities | 6,637.20 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Dimensional Fund Advisors Lp | 5.10 | ||
13G | Barrow Hanley Mewhinney & Strauss Llc | |||
13G/A | Vanguard Group Inc | 11.07 | 2.77 | |
13G/A | BlackRock, Inc. | 9.80 | 0.92 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
244,375 | 1,067,468 | 22.89 | |
157,682 | 714,216 | 22.08 | |
154,872 | 650,616 | 23.80 | |
(click for more detail) |
Similar Companies | |
---|---|
OGN – Organon & Co. | PBH – Prestige Consumer Healthcare Inc. |
PFE – Pfizer Inc. | QGEN – Qiagen N.V. |
RCUS – Arcus Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io